Patent intelligence · US
US 9931389
Genetic attenuation of plasmodium by B9 gene disruption
Genetic attenuation of plasmodium by B9 gene disruption
Patent details — US 9931389
- Jurisdiction
- US
- Status
- granted
- Grant date
- Apr 3, 2018
- Expiration
- Mar 29, 2038
- Applicant
- Sanaria Inc.
- Claims
- 20
- CPC classes
- A61K, A61K2039/522, A61K2039/545, A61K39/015
Quick answer
US 9931389 (Genetic attenuation of plasmodium by B9 gene disruption) is held by Sanaria Inc.. Status: granted. Granted Apr 3, 2018. Expires Mar 29, 2038 (12 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Sanaria Inc.
- Grant date
- Expiration
- Claims
- 20
- CPC classes
- A61K, A61K2039/522, A61K2039/545, A61K39/015
More from Sanaria Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12427199
Self-assembled diblock copolymers composed of pegmema and drug bearing polymeric segments
granted -
US 12409213
Live attenuated oral vaccine against shigellosis and typhoid fever
granted -
US 12246059
Stable hybrid FC fusion G-CSF formulation
granted -
US 12171822
Infectious plasmodium sporozoites grown in vitro
granted -
US 12156870
Antibody drug conjugates comprising sting agonists
granted -
US 12129288
Polynucleotides heterodimers of soluble interferon receptors and uses thereof
granted -
US 12077543
P2X3 and/or P2X2/3 compounds and methods
granted -
US 11987628
Methods and compositions for modulating CAR-T activity
granted
Frequently asked questions
What is US patent 9931389?
US 9931389 (Genetic attenuation of plasmodium by B9 gene disruption) is held by Sanaria Inc.. Status: granted. Granted Apr 3, 2018. Expires Mar 29, 2038 (12 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 9931389?
Sanaria Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 136 pharmaceutical patents for this assignee.
When does US 9931389 expire?
Our index shows an expiration date of Mar 29, 2038 (12 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.